IDNA vs. ARKG
Compare and contrast key facts about iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and ARK Genomic Revolution Multi-Sector ETF (ARKG).
IDNA and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. ARKG is an actively managed fund by ARK. It was launched on Oct 31, 2014.
Performance
IDNA vs. ARKG - Performance Comparison
Loading graphics...
IDNA vs. ARKG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 11.45% | 17.26% | -0.72% | -7.63% | -42.28% | -3.98% | 54.30% | 20.83% |
ARKG ARK Genomic Revolution Multi-Sector ETF | -6.49% | 23.04% | -28.24% | 16.22% | -53.90% | -33.92% | 180.40% | 11.53% |
Returns By Period
In the year-to-date period, IDNA achieves a 11.45% return, which is significantly higher than ARKG's -6.49% return.
IDNA
- 1D
- 0.48%
- 1M
- -5.56%
- YTD
- 11.45%
- 6M
- 20.68%
- 1Y
- 48.06%
- 3Y*
- 9.03%
- 5Y*
- -7.93%
- 10Y*
- —
ARKG
- 1D
- 2.54%
- 1M
- -9.43%
- YTD
- -6.49%
- 6M
- -6.10%
- 1Y
- 34.11%
- 3Y*
- -3.42%
- 5Y*
- -21.16%
- 10Y*
- 4.95%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
IDNA vs. ARKG - Expense Ratio Comparison
IDNA has a 0.47% expense ratio, which is lower than ARKG's 0.75% expense ratio.
Return for Risk
IDNA vs. ARKG — Risk / Return Rank
IDNA
ARKG
IDNA vs. ARKG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IDNA | ARKG | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.75 | 0.77 | +0.98 |
Sortino ratioReturn per unit of downside risk | 2.40 | 1.38 | +1.02 |
Omega ratioGain probability vs. loss probability | 1.29 | 1.16 | +0.13 |
Calmar ratioReturn relative to maximum drawdown | 3.66 | 1.11 | +2.55 |
Martin ratioReturn relative to average drawdown | 11.65 | 2.98 | +8.67 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| IDNA | ARKG | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.75 | 0.77 | +0.98 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.28 | -0.47 | +0.19 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.12 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.11 | 0.08 | +0.03 |
Correlation
The correlation between IDNA and ARKG is 0.85, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
IDNA vs. ARKG - Dividend Comparison
IDNA's dividend yield for the trailing twelve months is around 1.06%, while ARKG has not paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.06% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% | 0.00% | 0.00% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% |
Drawdowns
IDNA vs. ARKG - Drawdown Comparison
The maximum IDNA drawdown since its inception was -68.26%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for IDNA and ARKG.
Loading graphics...
Drawdown Indicators
| IDNA | ARKG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.26% | -83.59% | +15.33% |
Max Drawdown (1Y)Largest decline over 1 year | -12.11% | -27.51% | +15.40% |
Max Drawdown (5Y)Largest decline over 5 years | -68.26% | -80.18% | +11.92% |
Max Drawdown (10Y)Largest decline over 10 years | — | -83.59% | — |
Current DrawdownCurrent decline from peak | -45.05% | -75.76% | +30.71% |
Average DrawdownAverage peak-to-trough decline | -36.05% | -35.32% | -0.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.81% | 10.24% | -6.43% |
Volatility
IDNA vs. ARKG - Volatility Comparison
The current volatility for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) is 9.54%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 13.41%. This indicates that IDNA experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| IDNA | ARKG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.54% | 13.41% | -3.87% |
Volatility (6M)Calculated over the trailing 6-month period | 18.22% | 31.90% | -13.68% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.75% | 44.84% | -17.09% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 28.53% | 45.39% | -16.86% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.68% | 40.94% | -11.26% |